BRC 002
Alternative Names: BRC-002Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Biopharmaceutical Research Company
- Class Cannabinoids; Cyclohexenes; Hydroxybenzoic acids; Salicylic acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Complex regional pain syndromes
Most Recent Events
- 29 Jan 2025 US FDA reviews Chemistry, Manufacture and Controls (CMC) of BRC 002 for Complex regional pain syndromes
- 29 Jan 2025 Biopharmaceutical Research Company plans phase II trial in Complex regional pain syndromes by mid 2026
- 04 Dec 2024 BRC 002 receives Orphan Drug status for Complex regional pain syndromes in USA